---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-24-000605"
form_type: "8-K"
ticker: "IMUX"
cik: "0001280776"
company_name: "IMMUNIC, INC."
filed_at: "2024-05-08T23:59:59+00:00"
generated_at: "2026-06-02T08:49:36.497627+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Immunic reports Q1 2024 net loss $29.6M; cash extended into Q3 2025 on $240M private placement

## Summary
- Net loss $29.6M ($0.30/share) vs $25.3M ($0.58) in Q1 2023; R&D spend $18.7M, down 18% YoY.
- Cash $97.3M at March 31, 2024; runway into Q3 2025 after $240M private placement ($80M initial tranche).
- Phase 2 CALLIPER (progressive MS) top-line data expected April 2025; Phase 3 ENSURE readout Q2 2026 and H2 2026.
- Received fourth US patent for vidofludimus calcium (composition of matter) protecting into 2041.
- IMU-856 preparing for phase 2 in celiac disease after positive phase 1b data.

## SEC filing metadata
- accession: 0001193805-24-000605
- form_type: 8-K
- ticker: IMUX
- cik: 0001280776
- company_name: IMMUNIC, INC.
- filed_at: 2024-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1280776/000119380524000605/0001193805-24-000605-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1280776/000119380524000605/e663589_8k-immunic.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-24-000605
- JSON: https://secwatch.observer/filing/0001193805-24-000605.json
- Plain text: https://secwatch.observer/filing/0001193805-24-000605.txt

## Key facts
- Earnings Releases
  IMMUNIC, INC. reported financial results for the first quarter ended March 31, 2024.
  - Period: the first quarter ended March 31, 2024
  - Result: reported results
  source text: On May 8, 2024, Immunic, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024 and providing a corporate update
  evidence_url: https://www.sec.gov/Archives/edgar/data/1280776/000119380524000605/0001193805-24-000605-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.